Valneva’s Lyme Disease Jab Program Gets Pfizer Cash Boost
Through Equity Subscription Agreement
Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.
You may also be interested in...
Less than a year after signing a major advance purchase agreement to supply its inactivated COVID-19 jab to the EU, Valneva is faced with a termination that could hit its 2022 guidance.
The MHRA has become the first regulatory agency worldwide to grant a marketing authorization for the inactivated whole virus COVID-19 vaccine, VLA2001.
France’s Valneva has announced positive top-line Phase III data for its investigational chikungunya vaccine, and the NASDAQ- and Euronext-listed company looks set to launch the product next year.